PeptideHelper.org
Your evidence-based peptide reference
Research reference only. Not medical advice. Most compounds are not FDA-approved. Consult a qualified clinician before any human use.

Skin, Hair & Cosmetic

Melanotan I

Afamelanotide; Scenesse

Classification: MC1R agonist; EU/FDA-approved for EPP

Mechanism: Selective MC1R agonist; stimulates eumelanin production without sexual effects of MT-II

Benefits: Skin photoprotection; tanning; approved for erythropoietic protoporphyria

Evidence tier: FDA/EMA-Approved · Availability: Prescription (EPP)

Primary sources

  1. FDA Scenesse (afamelanotide) prescribing information
  2. Langendonk JG et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med 2015. PMID 26132941

Loading interactive view…